Previous studies have shown that the absence of GPVI protects mice from thrombo-inflammatory cerebral infarct growth in models of experimental stroke.5–8 Remarkably, however, although ACT017 has recently been tested in a clinical Phase 1b/2a trial in patients with AIS,23 no data on a therapeutic effect of Fab-mediated GPVI inhibition in experimental stroke have been reported to date. This evidence concerns the gene FANCB and Stroke.